Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease

NCT06088979

Active Not RecruitingPhase 2

Sponsor: Tourmaline Bio, Inc., a Novartis Company

Conditions: Thyroid Eye Disease

Interventions: TOUR006 - 20 MG, Placebo, TOUR006 - 50 MG

Countries: United States, Brazil, France, Italy, Jordan, Latvia, New Zealand, Puerto Rico

Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.

Eligibility overview

Sex: ALL

Age: 18 Years to 80 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Clinical diagnosis of Graves' disease associated with moderate to severe active TED
* Onset of active TED symptoms within approximately 15 months
* Proptosis (exophthalmos) ≥3 mm above the normal range per investigator judgment (based upon race and gender) for the study eye
* CAS ≥4 (on the 7-item scale) for the study eye
* Presence of TSI \>130% of the normal reference standard or \>0.55 IU/L (depending on assay method) and laboratory reference ranges

Additional inclusion criteria are defined in the study protocol.

Exclusion Criteria:

* Anticipated need for intervention due to sight-threatening complications or other significant and acute deterioration in vision
* Any previous treatment with teprotumumab or other agent that inhibits the IGF-1 receptor
* History of systemic (eg, oral or IV) steroid use with a cumulative dose equivalent to \>1 g of methylprednisolone for the treatment of TED. Previous oral steroid use with a cumulative dose of ≤1g methylprednisolone (or equivalent dosage for other systemic corticosteroid) for the treatment of TED, however, is allowed if the corticosteroid was discontinued at least 6 weeks before baseline (Day 1) and completely tapered by Baseline (if applicable).
* Systemic (oral or IV) corticosteroid use for conditions other than TED within 6 weeks of baseline (Day 1) or not completely tapered by baseline (if applicable).
* Any major illness/condition or evidence of an unstable clinical condition that, in the investigator's judgment, will substantially increase the risk to the participant, or confound the interpretation of safety assessments, if they were to participate in the study
* Any other condition that, in the opinion of the investigator, would impair the ability of the participant to comply with the study procedures or impair the ability to interpret data from the participant's participation in the study
* Pregnant or lactating

Additional exclusion criteria are defined in the study protocol.
Locations (36)
  • Tucson, Arizona, United States
  • Pasadena, California, United States
  • Sacramento, California, United States
  • San Francisco, California, United States
  • Aurora, Colorado, United States
  • Miami, Florida, United States
  • Boston, Massachusetts, United States
  • Livonia, Michigan, United States
  • Las Vegas, Nevada, United States
  • Hackensack, New Jersey, United States
  • New York, New York, United States
  • El Paso, Texas, United States
  • Fort Worth, Texas, United States
  • San Antonio, Texas, United States
  • Morgantown, West Virginia, United States
  • Belo Horizonte, Brazil
  • Goiânia, Brazil
  • Porto Alegre, Brazil
  • Porto Alegre, Brazil
  • Porto Alegre, Brazil
  • Rio de Janeiro, Brazil
  • São Paulo, Brazil
  • São Paulo, Brazil
  • Angers, France
  • Nantes, France
  • Naples, Italy
  • Pisa, Italy
  • Amman, Jordan
  • Riga, Latvia
  • Ventspils, Latvia
  • + 6 more on CT.gov